Tropical Medicine & International Health
February 2016 Volume 21, Issue 2 Pages 157–291
http://onlinelibrary.wiley.com/doi/10.1111/tmi.2016.21.issue-2/issuetoc

.

Original Article
Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings
Sachin N. Desai1,*, Zenebe Akalu2, Mekonnen Teferi2, Byomkesh Manna3, Samuel Teshome1,
Ju Yeon Park1, Jae Seung Yang1, Deok Ryun Kim1, Suman Kanungo3 and Laura Digilio1
Article first published online: 18 DEC 2015
DOI: 10.1111/tmi.12641
Summary
Studies on safety, immunogenicity and efficacy of the killed, bivalent whole cell oral cholera vaccine (Shanchol) have been conducted in historically endemic settings of Asia. Recent cholera vaccination campaigns in Haiti and Guinea have also demonstrated favourable immunogenicity and effectiveness in nonendemic outbreak settings. We performed a secondary analysis, comparing immune responses of Shanchol from two randomised controlled trials performed in an endemic and a less endemic area (Addis Ababa) during a nonoutbreak setting. While Shanchol may offer some degree of immediate protection in primed populations living in cholera endemic areas, as well as being highly immunogenic in less endemic settings, understanding the characteristics of immune responses in each of these areas is vital in determining ideal dosing strategies that offer the greatest public health impact to populations from areas with varying degrees of cholera endemicity.